TL1A Pathway: Embarking on New Frontiers in IBD Therapy with Biocytogen’s Humanized Mice
On December 17, Sanofi’s TL1A antibody, duvakitug, demonstrated success in a Phase IIb study, improving clinical remission rates in patients with moderate to severe ulcerative colitis and Crohn’s disease. Currently, several TL1A inhibitors—including monoclonal and bispecific antibodies such as tulisokibart, PF-07261271, and FG-M701—are in development to address unmet needs in the treatment of inflammatory bowel diseases (IBD).
Current TL1A Pipeline of Leading Multinational Corporations (MNCs)
TL1A (TNF-like cytokine 1A), encoded by the TNFSF15 gene, is a member of the TNF superfamily. By binding to death receptor 3 (DR3), TL1A activates pathways involved in cell proliferation, apoptosis, and cytokine production, playing a key role in maintaining the balance between innate and adaptive immune homeostasis.

TL1A is abnormally overexpressed in several autoimmune diseases, where it plays a significant role in the pathogenesis of conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases (IBD). Its unique mechanism of action positions it as a critical factor in both inflammatory responses and immune regulation. In the context of IBD, including ulcerative colitis and Crohn’s disease, TL1A has emerged as a highly promising therapeutic target, drawing considerable attention for its potential in treatment strategies.
TL1A-Related Mouse Models at Biocytogen
Biocytogen has developed a series of humanized mouse models targeting TL1A signaling pathways and established stable IBD models using diverse induction methods across various genetic backgrounds. These models support preclinical research and efficacy evaluation in IBD.
Case Study: B-hTL1A Mice
Protein expression analysis

TNBS-induced acute colitis in B-hTL1A mice

DSS-induced acute colitis in B-hTL1A mice

Case Study: B-hTL1A/hIL23A/hIL12B Mice
Protein expression analysis

DSS-induced IBD mouse model in B-hTL1A/hIL23A/hIL12B mice

There’s More
In addition to TL1A-related mouse models, Biocytogen has developed humanized models targeting other IBD-related pathways, as well as chemical-induced and adoptive transfer models of IBD. We also offer pharmacology services to support clinical evaluations and pathological analyses.
List of IBD-related targeted humanized mice at Biocytogen
IBD models and pharmacology services at Biocytogen
Contact us to learn more about Biocytogen’s IBD-related models and services!
References
Boyman, Onur, and Jonathan Sprent. “The role of interleukin-2 during homeostasis and activation of the immune system.” Nature Reviews Immunology 12.3 (2012): 180-190.
Zhang, Xiaohong, et al. “Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.” Immunity 8.5 (1998): 591-599.
Schluns, Kimberly S., Kimberly D. Klonowski, and Leo Lefrançois. “Transregulation of memory CD8 T-cell proliferation by IL-15Rα+ bone marrow–derived cells.” Blood 103.3 (2004): 988-994.
Yang, Ying, and Andreas Lundqvist. “Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy.” Cancers 12.12 (2020): 3586.
Holcomb, Erin A., and Weiping Zou. “A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.” The Journal of Clinical Investigation 132.3 (2022).
Waldmann, Thomas A. “The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.” Cancer immunology research 3.3 (2015): 219-227.